scispace - formally typeset
A

Aron H. Lichtman

Researcher at Virginia Commonwealth University

Publications -  242
Citations -  17326

Aron H. Lichtman is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cannabinoid & Cannabinoid receptor. The author has an hindex of 67, co-authored 232 publications receiving 15821 citations. Previous affiliations of Aron H. Lichtman include Scripps Research Institute & Dartmouth College.

Papers
More filters
Journal ArticleDOI

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

TL;DR: Results indicate that FAAH is a key regulator of anandamide signaling in vivo, setting an endogenous cannabinoid tone that modulates pain perception, and may represent an attractive pharmaceutical target for the treatment of pain and neuropsychiatric disorders.
Journal ArticleDOI

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

TL;DR: 2-AG endogenously modulates several behavioral processes classically associated with the pharmacology of cannabinoids and point to overlapping and unique functions for 2-AG and anandamide in vivo, indicating a functional segregation of endocannabinoid signaling pathways in vivo.
Journal ArticleDOI

Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation

TL;DR: These findings identify MAGL as a distinct metabolic node that couples endocannabinoid to prostaglandin signaling networks in the nervous system and suggest that inhibition of this enzyme may be a new and potentially safer way to suppress the proinflammatory cascades that underlie neurodegenerative disorders.
Journal ArticleDOI

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

TL;DR: A selective and efficacious dual FAAH/MAGL inhibitor is described and it is shown that this agent exhibits broad activity in the tetrad test for CB1 agonism, causing analgesia, hypomotilty, and catalepsy, indicating that AEA and 2-AG signaling pathways interact to regulate specific behavioral processes in vivo, including those relevant to drug abuse.